Zusammenfassung
Hintergrund
Osteosarkome werden multimodal behandelt. Bei nichtresektablen Osteosarkomen, insbesondere zentraler Tumorlokalisation, ist eine Radiotherapie des Primärtumors erforderlich. Die multimodale Therapie des Ewing-Sarkoms beinhaltet neben Polychemotherapie auch chirurgische und/oder strahlentherapeutische Lokaltherapie. Bei Irresektabilität stellt die definitive Strahlentherapie des Primärtumors die Therapie der Wahl dar.
Fragestellung
Ergebnisse einer definitiven Radiotherapie nichtresektabler Ewing-Sarkome und Osteosarkome werden erörtert.
Material und Methode
Es erfolgte eine Analyse der Literatur.
Ergebnisse
Bei nichtresektablen Osteosarkomen, insbesondere zentraler Tumorlokalisation am Körperstamm, ist eine primäre Strahlentherapie zusammen mit einer neoadjuvanten und Erhaltungschemotherapie Therapie der Wahl. Bei Einsatz moderner Bestrahlungstechniken und hoher Strahlendosen wurden lokale Kontrollraten von 60–70 % nach 5 Jahren beschrieben. Bei nichtresektablen Ewing-Sarkomen sollte nach einer Induktionschemotherapie die lokale Strahlentherapie des Primärtumors erfolgen. Dabei sollte das Bestrahlungsvolumen die initiale, prätherapeutische Tumorausdehnung berücksichtigen. Es werden Bestrahlungsdosen von 54–59,4 Gy empfohlen. Auf mögliche Interaktionen mit verwendeten Chemotherapeutika ist zu achten. Zusätzlich sollte bei einer pulmonalen Metastasierung eine Ganzlungenbestrahlung (15–18 Gy) durchgeführt werden.
Schlussfolgerungen
Eine definitive Radiotherapie von nichtresektablen Osteosarkomen soll mit modernen Bestrahlungstechniken, auch mit einer Partikeltherapie, unter Verwendung von hohen Strahlendosen über 70 Gy erfolgen. Die definitive Strahlentherapie stellt eine alternative Lokaltherapie nach Induktionschemotherapie bei Patienten mit inoperablen Ewing-Sarkomen dar.
Abstract
Background
Multimodal therapy is used to treat osteosarcoma. For unresectable osteosarcoma, definitive radiotherapy is necessary. Multimodal therapy for Ewing sarcoma includes multiagent chemotherapy and local treatment (surgery and/or radiotherapy). For unresectable tumors, radiotherapy of the primary tumor is used in the definitive management.
Objectives
Results of primary radiotherapy for unresectable Ewing sarcoma and osteosarcoma are discussed.
Materials and methods
An analysis of the literature was performed.
Results
For unresectable osteosarcoma, especially centrally located tumors, definitive radiotherapy in combination with neoadjuvant and maintenance chemotherapy is the treatment of choice. Using modern treatment techniques and high radiation doses, 5‑year local control rates of 60–70% have been reported. For unresectable Ewing sarcoma, definitive radiotherapy should be administered after neoadjuvant chemotherapy of the primary tumor. The irradiation volume must consider the initial, pretherapeutic extent of the tumor. Radiation doses of 54–59.4 Gy are recommended. Potential interactions with the administered chemotherapeutic agents must be taken into account. In addition, whole lung irradiation (15–18 Gy) is indicated in patients with pulmonary metastases.
Conclusions
For definitive radiotherapy of unresectable osteosarcoma, modern treatment techniques, including particle therapy, should be standard. High radiation doses over 70 Gy have to be delivered. For Ewing sarcomas, definitive radiotherapy is an alternative local treatment option after neoadjuvant chemotherapy.
Literatur
Anderton J, Moroz V, Marec-Berard P et al (2020) International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours—EURO EWING 2012 protocol. Trials 21:96
Andreou D, Ranft A, Gosheger G et al (2020) Which factors are associated with local control and survival of patients with localized pelvic ewing’s sarcoma? A retrospective analysis of data from the Euro-EWING99 trial. Clin Orthop Relat Res 478:290–302
Bolling T, Schuck A, Paulussen M et al (2008) Whole lung irradiation in patients with exclusively pulmonary metastases of Ewing tumors. Toxicity analysis and treatment results of the EICESS-92 trial. Strahlenther Onkol 184:193–197
Brown LC, Lester RA, Grams MP et al (2014) Stereotactic body radiotherapy for metastatic and recurrent ewing sarcoma and osteosarcoma. Sarcoma 2014:418270
Bruland OS, Skretting A, Solheim OP et al (1996) Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. Acta Oncol 35:381–384
Cangir A, Vietti TJ, Gehan EA et al (1990) Ewing’s sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing’s sarcoma studies. Cancer 66:887–893
Carrie C, Le Deley MC, Claude L, Alapetite C, Marandet J, Habrand JL, Quetin P, Oberlin O (2009) The radiosensitization effect and toxicity of busulfan containing chemotherapy before radiotherapy for Ewing’s sarcomas. Strahlenther Onkol 185(Sondernr. 2):31
Ciernik IF, Niemierko A, Harmon DC et al (2011) Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 117:4522–4530
Claude L, Carrie C, Alapetite C et al (2006) Toxicity of high-dose chemotherapy (busulfan-melphalan) followed by radiation therapy (Rt) in Ewing’s axial tumours: results of the French study. Pediatr Blood Cancer 49:555
Cotterill SJ, Ahrens S, Paulussen M et al (2000) Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 18:3108–3114
Delaney TF, Park L, Goldberg SI et al (2005) Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys 61:492–498
Dirksen U, Brennan B, Le Deley MC et al (2019) High-dose chemotherapy compared with standard chemotherapy and lung radiation in ewing sarcoma with pulmonary metastases: results of the European Ewing Tumour Working Initiative of National Groups, 99 trial and EWING 2008. J Clin Oncol 37:3192–3202
Dubois SG, Krailo MD, Gebhardt MC et al (2015) Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: a report from the Children’s Oncology Group. Cancer 121:467–475
Esiashvili N, Goodman M, Marcus RB Jr (2008) Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: surveillance epidemiology and end results data. J Pediatr Hematol Oncol 30:425–430
Franzius C, Schuck A, Bielack SS (2002) High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 20:1953–1954
Guadagnolo BA, Zagars GK, Raymond AK et al (2009) Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment. Cancer 115:3262–3270
Haeusler J, Ranft A, Boelling T et al (2010) The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 116:443–450
Hesla AC, Tsagozis P, Jebsen N et al (2016) Improved prognosis for patients with Ewing sarcoma in the sacrum compared with the innominate bones: the Scandinavian Sarcoma Group experience. J Bone Joint Surg Am 98:199–210
Anderton J, Moroz V, Marec-Berard P et al (2020) International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol. Trials 21(1):96
Kempf-Bielack B, Bielack SS, Jürgens H et al (2005) Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559–568
Laskar S, Basu A, Muckaden MA et al (2008) Osteosarcoma of the head and neck region: lessons learned from a single-institution experience of 50 patients. Head Neck 30:1020–1026
Letourneau PA, Shackett B, Xiao L et al (2011) Resection of pulmonary metastases in pediatric patients with Ewing sarcoma improves survival. J Pediatr Surg 46:332–335
Loeb DM, Garrett-Mayer E, Hobbs RF et al (2009) Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma. Cancer 115:2514–2522
Machak GN, Tkachev SI, Solovyev YN et al (2003) Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc 78:147–155
Matsunobu A, Imai R, Kamada T et al (2012) Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer 118:4555–4563
Mehta N, Selch M, Wang PC et al (2013) Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma. Sarcoma 2013:360214
Mohamad O, Imai R, Kamada T et al (2018) Carbon ion radiotherapy for inoperable pediatric osteosarcoma. Oncotarget 9:22976–22985
Mounessi FS, Lehrich P, Haverkamp U et al (2013) Pelvic Ewing sarcomas. Three-dimensional conformal vs. intensity-modulated radiotherapy. Strahlenther Onkol 189:308–314
Ozaki T, Flege S, Kevric M et al (2003) Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol 21:334–341
Paulino AC, Nguyen TX, Mai WY et al (2007) Dose response and local control using radiotherapy in non-metastatic Ewing sarcoma. Pediatr Blood Cancer 49:145–148
Paulussen M, Ahrens S, Burdach S et al (1998) Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 9:275–281
Paulussen M, Ahrens S, Craft AW et al (1998) Ewing’s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing’s Sarcoma Studies patients. J Clin Oncol 16:3044–3052
Rombi B, Delaney TF, Macdonald SM et al (2012) Proton radiotherapy for pediatric Ewing’s sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys 82:1142–1148
Schuck A, Ahrens S, Paulussen M et al (2003) Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 55:168–177
Schuck A, Ahrens S, Von Schorlemer I et al (2005) Radiotherapy in Ewing tumors of the vertebrae: treatment results and local relapse analysis of the CESS 81/86 and EICESS 92 trials. Int J Radiat Oncol Biol Phys 63:1562–1567
Schwarz R, Bruland O, Cassoni A et al (2009) The role of radiotherapy in oseosarcoma. Cancer Treat Res 152:147–164
Sterzing F, Stoiber EM, Nill S et al (2009) Intensity modulated radiotherapy (IMRT) in the treatment of children and adolescents—a single institution’s experience and a review of the literature. Radiat Oncol 4:37
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
S.E. Combs, K. Sommer und R. Schwarz geben an, dass kein Interessenkonflikt besteht.
Für diesen Beitrag wurden alle ethischen, rechtlichen und behördlichen Standards berücksichtigt.
Additional information
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Combs, S.E., Sommer, K. & Schwarz, R. Strahlentherapie nichtresektabler Knochentumoren. Onkologie 28, 572–577 (2022). https://doi.org/10.1007/s00761-022-01136-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-022-01136-5
Schlüsselwörter
- Osteosarkom
- Intensitätsmodulierte Radiotherapie
- Computergesteuerte Radiotherapie
- Ewing-Sarkom
- Stereotaktische Radiotherapie